US Edition
Published • loading... • Updated
Imbed Biosciences Secures Strategic Investment from BioLab Holdings
BioLab Holdings invests to broaden Imbed Biosciences' wound care reach in U.S. MD offices using proprietary antimicrobial technology to reduce complications, CEO said.
- In a press release, Imbed Biosciences announced a strategic investment from BioLab Holdings Inc., a Phoenix-based medical manufacturer, to expand its wound care product platform.
- BioLab Holdings invests in platforms that can elevate clinicians' wound-care approaches, said the company, to expand Imbed Biosciences' U.S. market reach and advance its antimicrobial solutions.
- Microlyte product targets chronic wounds and is engineered for bioburden reduction and cell proliferation, while Imbed's product portfolio aims to reduce infection risk, alleviate pain, and promote healing.
- The investment will expand Imbed's U.S. reach, particularly in MD office settings, and accelerate development of its SAM antimicrobial platform to reduce wound-care complications, companies say.
- The SAM™ Antimicrobial Technology platform positions Imbed Biosciences to advance patient outcomes through innovative synthetic solutions that differ from allograft-based products.
Insights by Ground AI
25 Articles
25 Articles
Imbed Biosciences Secures Strategic Investment from BioLab Holdings
MIDDLETON, Wis., Feb. 3, 2026 /PRNewswire/ -- Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences' reach within the…
Coverage Details
Total News Sources25
Leaning Left1Leaning Right0Center14Last UpdatedBias Distribution93% Center
Bias Distribution
- 93% of the sources are Center
93% Center
C 93%
Factuality
To view factuality data please Upgrade to Premium
